Skip to main content
  • U.S. Department of Health & Human Services
National Institutes of Health (NIH) - Turning Discovery into Health
  • NIH Employee Intranet
  • Staff Directory
  • En Español

Site Menu

  • Home
  • Health Information
    • Health Care Providers & Facilities
    • Health Info Lines
    • HealthCare.gov
    • Science Education Resources
    • NIH Clinical Research Trials and You
    • Talking to Your Doctor

    More »

    Quick Links

    • MedlinePlus Health Info
    • NIH News in Health
    • Wellness Toolkits
  • Grants & Funding
    • Grants Home Page
    • Find Funding
    • Due Dates
    • How to Apply
    • About Grants
    • Policy & Compliance
    • Grants News/Blog
    • Contracts
    • Loan Repayment

    More »

    Quick Links

    • RePORT
    • eRA Commons
    • NIH Common Fund
  • News & Events
    • News Releases
    • Digital Media Kits
    • Media Resources
    • Media Contacts
    • Images and B-roll
    • Events
    • Social Media

    More »

    Quick Links

    • NIH News in Health
    • NIH Research Matters
    • NIH Record
  • Research & Training
    • Medical Research Initiatives
    • Science Highlights
    • Science Education
    • Research in NIH Labs & Clinics
    • Training Opportunities
    • Library Resources
    • Research Resources
    • Clinical Research Resources
    • Safety, Regulation and Guidance

    More »

    Quick Links

    • PubMed
    • Stem Cell Information
    • OppNet
    • NIDB
    • NIH Blueprint for Neuroscience Research
  • Institutes at NIH
    • List of Institutes and Centers
    • NIH Office of the Director
    • Directors of NIH Institutes and Centers
    • NIH Institute and Center Contact Information

    More »

    Quick Links

    • NCI
    • NEI
    • NHLBI
    • NHGRI
    • NIA
    • NIAAA
    • NIAID
    • NIAMS
    • NIBIB
    • NICHD
    • NIDCD
    • NIDCR
    • NIDDK
    • NIDA
    • NIEHS
    • NIGMS
    • NIMH
    • NIMHD
    • NINDS
    • NINR
    • NLM
    • CC
    • CIT
    • CSR
    • FIC
    • NCATS
    • NCCIH
  • About NIH
    • Who We Are
    • What We Do
    • Jobs at NIH
    • Visitor Information
    • Frequently Asked Questions
    • Contact Us

    More »

    Quick Links

    • The NIH Director
    • The NIH Almanac
    • NIH…Turning Discovery Into Health®
    • Impact of NIH Research
    • Science, Health, and Public Trust

You are here

Home » News & Events » News Releases

News Releases

News Release

Wednesday, July 25, 2012

NIDA supports development of combined anti-heroin and HIV vaccine

Innovative dual-vaccine proposal wins 2012 Avant-Garde Award for Medications Development.

Heroin-HIV vaccine Diagram of the heroin vaccine portion of the heroin-HIV vaccine. The heroin-haptens are attached to tetanus toxoid mixed with liposomes containing phosphoryl lipid A, which is potent adjuvant formulation used to induce high titer antibodies to heroin.Dr. Gary R. Matyas

Dr. Gary R. Matyas has been selected the 2012 recipient of the NIDA Avant-Garde Award for Medications Development. Matyas proposes to develop an effective, safe and easily manufactured combination anti-heroin/HIV vaccine that could treat heroin addiction while at the same time prevent HIVinfection in those receiving the vaccine. Matyas will receive $1,000,000 per year for five years to support his research. He works at the Walter Reed Army Institute of Research (WRAIR) in Silver Spring, M.d. The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, announced the award today.

“This highly innovative dual-vaccine model would simultaneously address the intertwined epidemics of heroin abuse and HIV,” said NIDA Director Dr. Nora D. Volkow. “This is precisely the type of ground-breaking research NIDA's Avant-Garde program was designed to support. The implications for public health are enormous.”

The proposal stems from an existing research collaboration between NIDA and the U.S. Military HIV Research Program, part of the WRAIR. In 2010, the two organizations entered into an agreement to create a combination anti-heroin/HIV vaccine. The goal was to build upon previous preclinical research indicating that hapten-based anti-drug vaccines — in which a small molecule chemically similar to a drug of abuse (hapten) is bound to a protein carrier to induce an immune response — showed promise against a variety of abused drugs, including heroin. As a result of this collaboration, the heroin component of a combination anti-heroin/HIV vaccine has now been created and is ready for optimization and advanced preclinical testing. This current grant award will support this next phase of research and development. The award will beadministered through the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and work done in collaboration with the U.S. Military HIV Research Program and NIDA.

Dr. Gary R. MatyasDr. Gary R. Matyas

“Heroin use is strongly associated with a high risk of HIV infection and represents an increasingly important worldwide health problem,” stated Matyas. “The possibility of creating a combination heroin-HIV vaccine provides an important opportunity to address both a unique treatment for heroin abuse as well as continuing the quest to develop an effective preventive HIV vaccine.”

This research competition is an extension of NIDA's successful Avant-Garde Award for Innovative HIV/AIDS Research, now in its fifth year. Both competitions are intended to stimulate high-impact research that may lead to groundbreaking opportunities for the prevention and treatment of drug abuse. For further information about NIDA's Avant-Garde Award for Medications Development, please visit http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-12-010.html.

A statement from the NIDA Director on NIDA's commitment to vaccine development can be found at http://www.nida.nih.gov/about/welcome/Messagenicvax2.html.

Matyas is funded under grant number: DA034787.

The National Institute on Drug Abuse is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world's research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to inform policy and improve practice. Fact sheets on the health effects of drugs of abuse and information on NIDA research and other activities can be found on the NIDA home page at http://www.drugabuse.gov, which is now compatible with your smartphone, iPad or tablet. To order publications in English or Spanish, call NIDA's DrugPubs research dissemination center at 1-877-NIDA-NIH or 240-645-0228 (TDD) or fax or email requests to 240-645-0227 or drugpubs@nida.nih.gov. Online ordering is available at http://drugpubs.drugabuse.gov. NIDA's media guide can be found at http://drugabuse.gov/mediaguide, and its new easy-to-read website can be found at http://www.easyread.drugabuse.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health®

###

Institute/Center

National Institute on Drug Abuse (NIDA)

Contact

NIDA Press Office
301-443-6245

Connect with Us

  • Subscribe to news releases
  • RSS Feed

Connect with Us

  • Contact Us
  • Twitter
  • Facebook
  • Instagram
  • YouTube
  • Flickr
  • More Social Media from NIH

Footer

  • NIH Home
  • En Español
  • Site Map
  • Visitor Information
  • Frequently Asked Questions
  • Web Policies and Notices
  • NIH Website Archives
  • Freedom of Information Act
  • No Fear Act
  • HHS Vulnerability Disclosure
  • Office of Inspector General
  • USA.gov – Government Made Easy

NIH…Turning Discovery Into Health®

National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892

U.S. Department of Health and Human Services

Back to Top